Skip to main content

Day: March 26, 2025

Duluth Holdings Inc. Announces Retirement of Director

MOUNT HOREB, Wis., March 26, 2025 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading” or the “Company”) (NASDAQ: DLTH), a lifestyle brand of men’s and women’s workwear, casual wear, outdoor apparel and accessories, today announced the retirement of Francesca M. Edwardson as a member of the Board of Directors. Ms. Edwardson informed the Company that she had independently decided not to stand for re-election to the Company’s Board of Directors at the 2025 Annual Meeting of Shareholders. Ms. Edwardson, age 67, has been a member of the Board of Directors since September 2015 and had served on the Company’s advisory board since July 2015. Ms. Edwardson will continue to serve as a member of the Board of Directors until the close of the 2025 Annual Meeting of Shareholders. Stephen L. Schlecht, Chairman...

Continue reading

Temenos continues to top ESG ratings from Dow Jones, S&P Global, Sustainalytics and CDP

Consistently strong ESG ratings reflect Temenos’ leadership in sustainability for the banking industry GRAND-LANCY, Switzerland, March 26, 2025 (GLOBE NEWSWIRE) — Temenos (SIX: TEMN), a global leader in mission-critical solutions for financial institutions, today announced that it has been recognized once again as a global sustainability leader by the top ESG ratings agencies. Temenos achieved the top score in the Software industry for the third year running in the 2024 Dow Jones Best-in-Class Indices (DJBICI) and was once again the only software company to be awarded a top 1% distinction in the S&P Global Sustainability Yearbook. Temenos was also classified as low risk in the Sustainalytics ESG Risk Rating Report and rated A- for climate by the Carbon Disclosure Project (CDP). These strong results from a range of respected...

Continue reading

URW announces the launch of a tender offer on some of its outstanding hybrid notes and a new issue of Euro-denominated hybrid notes

Paris, March 26, 2025 Press release URW announces the launch of a tender offer on some of its outstanding hybrid notes and a new issue of Euro-denominated hybrid notes Description of the transaction UNIBAIL-RODAMCO-WESTFIELD SE (“URW” or the “Group”) announces today its intention to issue new Euro denominated Deeply Subordinated Perpetual Fixed Rate Resettable Perp-NC 5.5 hybrid notes (the “New Notes”), guaranteed by URW NV, and a concurrent tender offer (the “Tender Offer”) on its:€995,000,000 7.250% Hybrid Perp-NC 2028 notes (ISIN: FR001400IU83) (“NC2028 Notes”); and €750,000,000 2.875% Hybrid Perp-NC 2026 notes (ISIN: FR0013330537) (“NC2026 Notes” and together with the NC2028 Notes, the “Existing Notes”)URW intends to purchase its NC2028 Notes up to the sum of the New Notes’ aggregate principal amount plus €184 Mn. Additionally,...

Continue reading

2024 Preliminary Results

Kenmare Resources plc (“Kenmare” or the “Company” or “the Group”) 26 March 2025 2024 PRELIMINARY RESULTS Kenmare Resources plc (LSE:KMR, ISE:KMR), one of the leading global producers of titanium minerals and zircon, which operates the Moma Titanium Minerals Mine (the “Mine” or “Moma”) in northern Mozambique, today announces its preliminary results for the 12 months to 31 December 2024. Statement from Tom Hickey, Managing Director: “In 2024, Kenmare delivered EBITDA of $157 million, supporting our ability to fund our capital programme and continue to make shareholder distributions. As such, the Board is proposing a full year dividend of USc32 per share for 2024, bringing shareholder distributions to $295 million since 2019. With 2025 well underway, we are on track to achieve our annual production guidance. Production...

Continue reading

ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Designed to Restore Standing, Stepping, and Lower Limb Mobility

The ARC-IM Lumbar Lead is the second model in the ARC-IM Lead family to be used in a clinical feasibility study The Company is building a portfolio of purpose-designed leads to optimize delivery of ARC-IM Therapy at various locations along the spinal cord to enable restoration of movement and other functions EINDHOVEN, the Netherlands, March 26, 2025 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces the first human implant of its investigational ARC-IM® Lumbar Lead. This milestone procedure was performed on March 17, 2025, by Dr. Jocelyne Bloch, Chief of Neurosurgery at Lausanne University Hospital (CHUV)...

Continue reading

BW Offshore: Closing of the sale of the FPSO BW Pioneer

Closing of the sale of the FPSO BW Pioneer Reference is made to the announcement dated 12 March 2025, in which BW Offshore Limited (“BW Offshore”) announced its agreement to sell the FPSO BW Pioneer for USD 125 million to a subsidiary of Murphy Oil Corporation (NYSE: MUR). Following the close of the transaction, BW Offshore has received the initial payment of USD 100 million. The remaining balance is expected before end of Q2 2025 when certain contractual obligations are met. The two parties have also signed a five-year reimbursable O&M contract, under which BW Offshore will continue to provide operations and maintenance services. For further information, please contact:Ståle Andreassen, CFO, +47 91 71 86 55 IR@bwoffshore.com or www.bwoffshore.com About BW Offshore:BW Offshore engineers innovative floating production solutions. The...

Continue reading

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

Chlamydia vaccine candidate granted fast track designation by the US FDAChlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertility A phase 1/2 clinical study evaluating the immunogenicity and safety of the vaccine candidate is due to start in coming daysParis, March 26, 2025. The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The decision was based on the potential of the vaccine candidate to address a serious condition and address an unmet public health need. The chlamydia vaccine candidate has been designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. Following a promising pre-clinical program, Sanofi...

Continue reading

Facephi Leads NIST Ranking, Outperforming Top Biometric Technology Providers in Accuracy and Efficiency

Facephi Leads NIST Ranking, Outperforming Top Biometric Technology Providers in Accuracy and EfficiencyFacephi’s latest Software Development Kit (SDK) has achieved a significant boost in precision, securing a leading position in NIST’s global ranking. Its biometric engine ensures a security threshold of 1 in a 1,000,000, drastically reducing the risk of identity fraud. The technology excels in challenging conditions, including aging detection and facial recognition at extreme angles.Alicante, March 26th, 2025 – Facephi Biometría, SA (BME Growth: FACE; Euronext Growth Paris: ALPHI) (“Facephi” or the “Company”), a Spanish tech leader in global digital identity protection and verification, announces that it has secured a top position in the latest NIST ranking, surpassing major biometric technology providers and reinforcing its...

Continue reading

GAM announces 2024 full year results

26 March 2025 PRESS RELEASE Ad hoc announcement pursuant to Art. 53 Listing Rules: GAM announces 2024 full year results Strong progress in implementing turnaround strategy. GAM continues to target profitability in fiscal year 2026. Financial Highlights for Full Year 2024IFRS net loss of CHF 70.9 million compared to CHF 82.1 million for FY 2023. Underlying loss before tax of CHF 66.8 million compared to CHF 49.5 million for FY 2023. AuM at CHF 16.3 billion compared to CHF 19.3 billion as at 31 December 2023. Cost optimisation initiatives across the business resulted in a 20% decrease in underlying expenses compared to FY 2023. The full impact of these cost optimisation initiatives will be reflected in FY 2025 and beyond. Successful CHF 100 million rights issue completed in November 2024, which resulted in our anchor shareholder, NJJ Holding...

Continue reading

Mowi ASA: Integrated Annual Report 2024

Mowi has today published its 2024 Integrated Annual Report, including sustainability reporting and complete 2024 annual accounts with notes. The integrated report is attached, available in European Single Electronic Format (ESEF) and has been published on www.mowi.com/investors/reports/ The Green Financing Impact Report in relation to Mowi’s Green Bond issuance has also been published today and is available on our website www.mowi.com/investors/share-and-bond/bonds/ This information is subject to the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.         AttachmentsMowi Integrated Annual Report 2024mowi-2024-12-31-en

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.